Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2015 1
2016 1
2018 1
2019 1
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for patricia duchenne
Your search for Patricia Duchesne retrieved no results
Psychosocial adjustment and parental stress in Duchenne Muscular Dystrophy.
Gocheva V, Schmidt S, Orsini AL, Hafner P, Schaedelin S, Weber P, Fischer D. Gocheva V, et al. Eur J Paediatr Neurol. 2019 Nov;23(6):832-841. doi: 10.1016/j.ejpn.2019.09.008. Epub 2019 Sep 20. Eur J Paediatr Neurol. 2019. PMID: 31585833
OBJECTIVE: This cross-sectional study aimed to assess psychosocial adjustment of children with Duchenne Muscular Dystrophy (DMD) and to explore its possible association to parental stress. ...
OBJECTIVE: This cross-sectional study aimed to assess psychosocial adjustment of children with Duchenne Muscular Dystrophy (DMD) and …
Induced pluripotent stem cells for modeling neurological disorders.
Russo FB, Cugola FR, Fernandes IR, Pignatari GC, Beltrão-Braga PC. Russo FB, et al. World J Transplant. 2015 Dec 24;5(4):209-21. doi: 10.5500/wjt.v5.i4.209. World J Transplant. 2015. PMID: 26722648 Free PMC article. Review.
Here, we review the accomplishments and the current progress in human neurological disorders by using iPSC modeling for Alzheimer's disease, Parkinson's disease, Huntington's disease, spinal muscular atrophy, amyotrophic lateral sclerosis, duchenne muscular dystrophy, schi …
Here, we review the accomplishments and the current progress in human neurological disorders by using iPSC modeling for Alzheimer's disease, …
RhoA/ROCK2 signalling is enhanced by PDGF-AA in fibro-adipogenic progenitor cells: implications for Duchenne muscular dystrophy.
Fernández-Simón E, Suárez-Calvet X, Carrasco-Rozas A, Piñol-Jurado P, López-Fernández S, Pons G, Bech Serra JJ, de la Torre C, de Luna N, Gallardo E, Díaz-Manera J. Fernández-Simón E, et al. J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1373-1384. doi: 10.1002/jcsm.12923. Epub 2022 Feb 7. J Cachexia Sarcopenia Muscle. 2022. PMID: 35132805 Free PMC article.
BACKGROUND: The lack of dystrophin expression in Duchenne muscular dystrophy (DMD) induces muscle fibre and replacement by fibro-adipose tissue. ...
BACKGROUND: The lack of dystrophin expression in Duchenne muscular dystrophy (DMD) induces muscle fibre and replacement by fibro-adip …
Implementation of Motor Function Measure score percentile curves - Predicting motor function loss in Duchenne muscular dystrophy.
Hafner P, Schmidt S, Schädelin S, Rippert P, Hamroun D, Fabien S, Henzi B, Putananickal N, Rubino-Nacht D, Vuillerot C, Fischer D; MFM registry Study Group. Hafner P, et al. Eur J Paediatr Neurol. 2022 Jan;36:78-83. doi: 10.1016/j.ejpn.2021.11.004. Epub 2021 Dec 14. Eur J Paediatr Neurol. 2022. PMID: 34929615 Free article.
The Motor Function Measure is a standardized scoring system to evaluate motor function and monitor disease progression in neuromuscular diseases such as Duchenne muscular dystrophy. There are no available reference percentile curves for this measure. The aim of this analys …
The Motor Function Measure is a standardized scoring system to evaluate motor function and monitor disease progression in neuromuscular dise …
Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
Hafner P, Bonati U, Rubino D, Gocheva V, Zumbrunn T, Gueven N, Fischer D. Hafner P, et al. Trials. 2016 Aug 3;17(1):389. doi: 10.1186/s13063-016-1503-1. Trials. 2016. PMID: 27488051 Free PMC article. Clinical Trial.
BACKGROUND: Duchenne muscular dystrophy (DMD) is an X-linked recessive disease that affects 1 in 3500-6000 male births. ...
BACKGROUND: Duchenne muscular dystrophy (DMD) is an X-linked recessive disease that affects 1 in 3500-6000 male births. ...
Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy.
Guerron AD, Rawat R, Sali A, Spurney CF, Pistilli E, Cha HJ, Pandey GS, Gernapudi R, Francia D, Farajian V, Escolar DM, Bossi L, Becker M, Zerr P, de la Porte S, Gordish-Dressman H, Partridge T, Hoffman EP, Nagaraju K. Guerron AD, et al. PLoS One. 2010 Jun 21;5(6):e11220. doi: 10.1371/journal.pone.0011220. PLoS One. 2010. PMID: 20574530 Free PMC article.
BACKGROUND: The number of promising therapeutic interventions for Duchenne Muscular Dystrophy (DMD) is increasing rapidly. One of the proposed strategies is to use drugs that are known to act by multiple different mechanisms including inducing of homologous fetal form of a …
BACKGROUND: The number of promising therapeutic interventions for Duchenne Muscular Dystrophy (DMD) is increasing rapidly. One of the …
Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy.
Piñol-Jurado P, Suárez-Calvet X, Fernández-Simón E, Gallardo E, de la Oliva N, Martínez-Muriana A, Gómez-Gálvez P, Escudero LM, Pérez-Peiró M, Wollin L, de Luna N, Navarro X, Illa I, Díaz-Manera J. Piñol-Jurado P, et al. Cell Death Dis. 2018 Jul 10;9(7):776. doi: 10.1038/s41419-018-0792-6. Cell Death Dis. 2018. PMID: 29991677 Free PMC article.
Duchenne muscle dystrophy (DMD) is a genetic disorder characterized by progressive skeletal muscle weakness. ...
Duchenne muscle dystrophy (DMD) is a genetic disorder characterized by progressive skeletal muscle weakness. ...